A retrospective single center study was performed on 516 trephine biopsies derived from
160 patients with stable phase Ph+-CML and allogeneic BMT. Following morphometric …

An immunohistochemical and morphometric study was performed on 363 trephine biopsies
of the bone marrow derived from 127 patients with chronic myeloid leukemia at standardized …

Factors predicting allogeneic hematopoietic cell transplantation (HCT) outcomes in
myelofibrosis in the early post-HCT period have not been defined thus far. We attempt to …

Hematopoietic cell transplantation (HCT) is a curative approach for myelofibrosis patients,
but relapse is a major cause of treatment failure. We investigated the effect of donor …

In this cross-sectional study, we retrospectively evaluated the files of 227 patients with
myelofibrosis who underwent transplantation between 1994 and 2015 for relapse later than …

Scant knowledge exists about the dynamics of fibro-osteosclerotic bone marrow (BM)
lesions and regeneration of hematopoiesis following allogeneic peripheral stem cell …

A retrospective study compared posttransplant engraftment parameters in 203 patients with
myelofibrosis (MF) with those in a population of 203 matched controls without MF. There …

A clinicopathological study was conducted on 351 bone marrow trephine biopsies derived
from 124 patients with chronic myeloid leukemia (CML) at standardized endpoints before …

Allogeneic hematopoieteic stem cell transplantation (HSCT) is the only curative treatment for
myelofibrosis (MF), but it is still associated with significant risks and complications. One of …

Despite the curative potential of allogeneic hematopoietic cell transplantation (HCT) for
myelofibrosis (MF), a significant number of patients with MF do not undergo HCT. Factors …